[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:apol1-mediated-kidney-disease":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":24,"states":25},"APOL1-mediated kidney disease",2,1,[8,16],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT05312879","Phase 2\u002F3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1-Mediated Proteinuric Kidney Disease",[12],"Phase 2\u002FPhase 3","RECRUITING","2026-08-26T02:16:31.714843Z","2026-05-05T02:43:28.556766Z",{"nct_id":17,"title":18,"phases":19,"status":21,"updated_at":22,"content_modified":23},"NCT06794996","Inaxaplin in Participants With Proteinuric APOL1 Mediated Kidney Disease With or Without Comorbidities",[20],"Phase 2","ACTIVE_NOT_RECRUITING","2026-08-03T00:58:58.946605Z","2026-07-05T20:59:06.676789Z",[],[]]